• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
JNJ
Biotech

J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo

J&J has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye drug Vabysmo.
Nick Paul Taylor Nov 16, 2026 9:40am
Eli Lilly booth at ASCO 2026

Lilly gets fresh myelofibrosis option via $1.5B Calytrix buyout

Nov 16, 2026 9:49am
China flag against blue sky

Chinese scientists fired after child dies in gene editing study

Nov 16, 2026 4:30am
Graphic of a number of arrows missing the bullseye on a target except for one arrow

CG’s newest late-stage bladder cancer results broaden potential

Nov 16, 2026 2:05pm
A puzzle of the brain with one missing piece

Helus scores ph. 3 depression win for modified psychedelic

Nov 16, 2026 10:40am
Biogen AAIC

Biogen inks $411M pact for TrimTech’s protein degrader skills

Nov 16, 2026 10:00am
More News

Aclaris drops TSLP program after failing ph. 2 eczema test

Nov 16, 2026 8:20am

Flagship commits £100M for London biotech incubation outpost

Nov 16, 2026 6:09am

DNA med-focused biotech Seawolf surfaces with $1.2B Sanofi pact

Nov 16, 2026 5:00am

Sofinnova books $815M fund toward up-and-coming ‘global leaders’

Nov 16, 2026 2:00am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings